Summary of Shareholders Equity Warrants Outstanding (Details) - shares |
12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
|||||||||
| Equity [Abstract] | ||||||||||
| Shares Outstanding, beginning | 1,328,000 | [1] | 5,397,000 | |||||||
| Shares Issued | ||||||||||
| Shares Exercised | (320,000) | [2] | (2,549,000) | |||||||
| Shares Tendered | ||||||||||
| Shares Expired | (20,000) | (1,493,000) | ||||||||
| Shares Outstanding, ending | 988,000 | [3] | 1,328,000 | [1] | ||||||
| ||||||||||
| X | ||||||||||
- Definition Share-based compensation arrangement by share based payment award non-option equity instruments tendered. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|